A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

November 30, 2027

Conditions
Parkinson Disease
Interventions
BIOLOGICAL

STEM-PD

STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.

Trial Locations (2)

214 28

Region Skåne - Skåne University Hospital, Lund

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

All Listed Sponsors
collaborator

Lund University

OTHER

collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

collaborator

University of Cambridge

OTHER

lead

Region Skane

OTHER